About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

NCT00771329·6 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Biogen

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of adult onset RA (functional class I-III) for at least 6 months
Must have been treated with and be tolerating Methotrexate (5-25 mg/week) for 3 months, at a stable dose for at least 4 weeks
Must have at least 4 swollen and tender joints due to rheumatoid arthritis

You may not be if

History of recurrent infections requiring antibiotic treatment within 12 months
Serious local infection or systemic infection within 3 months
Suffering from rheumatic or autoimmune disease other than RA
History of cancer, heart failure, kidney disease, liver disease, HIV infection, tuberculosis or other serious illness

The record

StatusCompleted

PhasePhase 1

Taking part53

StartedOct 2008

UpdatedSep 16, 2013

Conditions

Rheumatoid Arthritis

Where6

Research Site
Anniston, Alabama, United States
Research Centre
Palm Desert, California, United States
Research Site
Oklahoma City, Oklahoma, United States